Browse studies

Find your next paid study

10 recruiting studies matching your filters

Genome Transplant Dynamics

Study Description: Heart and lung transplants can save lives, but long-term success is often limited by organ rejection that is hard to detect early. This stu…

Thoracic Organ Transplantation

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT02423070

Observational

Feeding the Flame, One Day at a Time: Design and Acceptability of a Serious Game to Support Medication Adherence and Education for Pediatric Solid Organ Transplant Patients

Children and teenagers who receive a solid organ transplant (such as a kidney, liver, or heart) must take medications every day to keep their new organ healthy…

Solid Organ Transplant

Estimated

~$10 – $6,250

Stanford UniversityNCT07609303

Phase 1

Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic …

Allogeneic Hematopoietic Stem Cell Transplantation RecipientCytomegalovirusDonor+2 more

Estimated

~$10 – $7,500

Sumithira VasuNCT03665675

Immune Monitoring and Assay Development in Organ Transplant Recipients

The purpose of this study to develop a well-characterized library of blood, biopsy tissue, and urine samples from transplant patients. Subjects without transpl…

Organ TransplantationTransplantation Immunology

Estimated

~$10 – $750

Emory UniversityNCT01283295

Phase 3

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-ass…

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more

Estimated

~$10 – $7,500

Pierre Fabre MedicamentNCT03394365

Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection

The objective of this study is to evaluate whether certain proteins, expressed in biological tissues can indict a better understanding of the effect of drugs t…

Solid Organ TransplantationBone Marrow Transplantation

Estimated

~$10 – $750

University of PittsburghNCT01163578

Phase 1

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients This study is designed to evaluate whether a…

Skin CancerCutaneous Squamous Cell Carcinoma (CSCC)Actinic Keratosis (AK)+1 more

Estimated

~$10 – $7,500

Marissa LoblNCT07286318

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recen…

Hematopoietic Cell TransplantSolid Organ TransplantRespiratory Viral Infection

Estimated

~$10 – $750

Arkansas Children's Hospital Research InstituteNCT05550298

Phase 4

Exploratory Use of CMV Immunoglobulin in High Risk (D+R-) Transplant Recipients at the End of Antiviral Prophylaxis to Decrease the Risk of Late CMV Infection

This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipi…

CytomegalovirusOrgan TransplantKidney Transplant; Complications+2 more

Estimated

~$10 – $7,500

Camille N. Kotton, MDNCT06958796

Phase 4

A Pilot Trial of the Tolerability and Clinical Effectiveness of Letermovir When Used for Secondary Prophylaxis to Prevent Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following …

Cytomegalovirus InfectionsInfection in Solid Organ Transplant RecipientsNeutropenia+1 more

Estimated

~$10 – $6,250

Tufts Medical CenterNCT05626530